# Protalix BioTherapeutics, Inc.: Form 10-K for the period ended Dec 31, 2016

- Company: [Protalix BioTherapeutics, Inc.](/companies/plx.md) (CIK 1006281)
- Form: 10-K
- Filed: 2017-03-16
- Accepted by EDGAR: Mar 16, 2017, 16:08 ET
- Period: 2016-12-31
- Accession: 0001144204-17-015083
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006281/000114420417015083/v461290_10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006281/000114420417015083/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2016-01-01 to 2016-12-31 | $9.2m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2016-01-01 to 2016-12-31 | $8.4m | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2016-01-01 to 2016-12-31 | $801.0k | us-gaap:GrossProfit |
| Research and development | 12 months, 2016-01-01 to 2016-12-31 | $30.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2016-01-01 to 2016-12-31 | $9.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2016-01-01 to 2016-12-31 | −$33.2m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months, 2016-01-01 to 2016-12-31 | −$29.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2016-01-01 to 2016-12-31 | −$0.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2016-01-01 to 2016-12-31 | −$32.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2016-01-01 to 2016-12-31 | $849.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-12-31 | $63.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $71.9m | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $82.2m | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $66.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-12-31 | $92.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-12-31 | −$10.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1006281/000114420417015083/v461290_10k.htm

Filed Mar 16, 2017.
Source: SEC EDGAR, the filing index for accession 0001144204-17-015083. Last ingested by Listed: Nov 10, 2026, 16:48 ET. No prices; not investment advice.
